Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS

MONDAY, July 6, 2026-- For patients with newly diagnosed relapsing multiple sclerosis and recent disease activity, rituximab is noninferior to ocrelizumab for suppressing disease activity, according to a study published in the July 2 issue of the...